Novo Nordisk's Wegovy Sales Surge on Crucial US Market.

Novo Nordisk A/S experienced a significant increase in sales of the weight-loss drug Wegovy in the third quarter, surpassing analyst estimates. Despite concerns from investors about prescription numbers and the potential impact of a new obesity treatment, Novo's sales surged, particularly in the US market. The company is competing with Eli Lilly & Co. in the rapidly growing obesity drug market, with expectations that the industry will reach $130 billion by the end of the decade. Novo is working to address drug shortages and increase production capacity to meet demand, while also focusing on expanding reimbursement from insurers for their products. [Extracted from the article]